Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

@article{Ge2009GeneticVI,
  title={Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance},
  author={D. Ge and J. Fellay and A. Thompson and J. Simon and K. Shianna and T. Urban and E. Heinzen and P. Qiu and A. Bertelsen and A. Muir and M. Sulkowski and J. McHutchison and D. Goldstein},
  journal={Nature},
  year={2009},
  volume={461},
  pages={399-401}
}
Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-α-2b (PegIFN-α-2b) or -α-2a (PegIFN-α-2a) combined with ribavirin (RBV), it is well known that many patients will not be cured by treatment, and that patients of European ancestry have a significantly higher probability of being cured than patients of African… Expand

Paper Mentions

Interventional Clinical Trial
Background: Hepatitis C recurrence, which invariably occurs in viremic liver transplant (LT) recipients, associated with accelerated liver fibrosis leading to established graft… Expand
ConditionsHepatitis C Recurrence After Liver Transplant
InterventionDrug
Interventional Clinical Trial
Objective: Pegulated Interferon α2 plus ribavirin is a treatment of choice in patients with chronic hepatitis C infection. This study was conducted to find out the frequency of… Expand
ConditionsHepatitis C, Hepatitis C Relapse
InterventionDrug
Observational Clinical Trial
More than 1.5 millions individuals are infected with HCV in Italy. They are at risk to develop related morbidity and mortality from cirrhosis and hepatocellular carcinoma, unless… Expand
ConditionsLiver Disease
InterventionGenetic
Snipping away at hepatitis C
HEPATOLOGY ELSEWHERE EDITORSKris Kowdley , Seattle , WA
Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infectionExpand
IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.
TLDR
A association between genetic variation in the region of the IL28B gene and treatment outcome in HCV-1 patients and patients who carry the good response variant are two- to three-fold more likely to be cured. Expand
The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection
TLDR
The pharmacogenetic data for boceprevir and telaprevir triple therapy in patients with HCV‐1 infection, as well as viral genomic polymorphisms and genetic variants that may protect against anemia are reviewed. Expand
Pharmacogenetics: A SNP for hepatitis C treatment failure
TLDR
In patients who have the marker that is associated with treatment failure, the levels of IL28 mRNA in the blood were significantly lower than in individuals who did not carry the marker, which suggests that the causal variants might affect the expression of this gene. Expand
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.
TLDR
The SNP rs12979860 is strongly associated with SVR in patients infected with HCV-4, but not with liver disease severity; analysis of IL28B genotype might be used to guide treatment for these patients. Expand
Immunologic al and Genetic Markers Predicting Treatment Outcome in Hepatitis C Virus Infection
Hepatitis C is a blood-borne infection caused by the hepatitis C virus (HCV). A chronic infection, which develops in most infected subjects, may lead to liver cirrhosis with ensuing liver dysfunctionExpand
Effect of IL28B genotype on hepatitis B and C virus infection.
TLDR
This work has found an association between IL28B genotype and spontaneous viral clearance in acute HCV infection and the effect on sustained viral response (SVR) could also be observed in patients receiving a triple-therapy with a direct antiviral agent (DAA) combined with PEG-IFN/RBV. Expand
IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients
TLDR
SVR as a hepatitis C treatment outcome can be predicted by various baseline predictors such as HCV RNA levels, the dose and duration of therapy, body mass index, age, insulin resistance, gender, stage of fibrosis and co-infection with other hepatitis viruses or HIV. Expand
Genetics of IL28B and HCV—response to infection and treatment
TLDR
Current understanding of the role of IL28B in HCV infection and response to therapy is summarized and hepatic expression levels ofIL28B and interferon-stimulated genes seem to be reduced at baseline, but are induced more strongly after IFN-α administration, perhaps resulting in more effective elimination of the virus. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
TLDR
The data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α. Expand
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
TLDR
It is shown that the C/C genotype strongly enhances resolution of HCV infection among individuals of both European and African ancestry, the strongest and most significant genetic effect associated with natural clearance ofHCV. Expand
Interferon signaling and treatment outcome in chronic hepatitis C
TLDR
The concept that activation of the endogenous IFN system in CHC not only is ineffective in clearing the infection but also may impede the response to therapy, most likely by inducing a refractory state of the IFN signaling pathway, is supported. Expand
Gene expression and hepatitis C virus infection
TLDR
This paper reviews the published literature on gene expression associated with HCV infection (HCV infection, fibrosis progression), and also according to response to treatment, and recommends combination of pegylated interferons with ribavirin for treatment of hepatitis C. Expand
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
BACKGROUND & AIMS The most effective therapy currently available for treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin. This study evaluated theExpand
Intrahepatic interferon‐stimulated gene responses: Can they predict treatment responses in chronic hepatitis C infection?
TLDR
The authors have identified molecular pathways associated with IFN responsiveness within the liver associated with HCV infection through gene array analysis and confirmed key findings by real-time reverse-transcription polymerase chain reaction. Expand
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.
TLDR
Black patients with chronic hepatitis C have a lower rate of response to treatment with peginterferon alfa-2b and ribavirin than non-Hispanic white patients, a difference that is not explained by differences in the viral genotype. Expand
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
TLDR
Treatment with a telaprevir-based regimen significantly improved sustained virologic response rates in patients with genotype 1 HCV, albeit with higher rates of discontinuation because of adverse events. Expand
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
  • Chen-Hua Liu, Chun-Jen Liu, +11 authors J. Kao
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
TLDR
In treatment-naive Asian patients with HCV-1 infection, 48 weeks of pegylated IFN-alpha-2a plus ribavirin therapy is associated with a higher SVR rate, compared with 24 weeks of such therapy. Expand
Treatment responses in Asians and Caucasians with chronic hepatitis C infection.
TLDR
Genotype 1 CHC in Asian subjects is associated with higher rates of virological response compared to that in Caucasians, and this difference remained significant after adjusting for other predictive variables. Expand
...
1
2
3
4
5
...